Dr. David Berg MD Senior Fellow in Cardiovascular Medicine and Critical Care Medicine Brigham and Women’s Hospital Postdoctoral Research Fellow with the TIMI Study Group.

SGLT2 Inhibitors Reduced Risk of Heart Failure Hospitalization in Patients with Type 2 Diabetes

MedicalResearch.com Interview with:

Dr. David Berg MD Senior Fellow in Cardiovascular Medicine and Critical Care Medicine Brigham and Women’s Hospital Postdoctoral Research Fellow with the TIMI Study Group.

Dr. David Berg

Dr. David Berg MD
Senior Fellow in Cardiovascular Medicine and
Critical Care Medicine
Brigham and Women’s Hospital
Postdoctoral Research Fellow with the TIMI Study Group.

MedicalResearch.com: What is the background for this study?

Response: Heart failure is a frequent and important complication of type 2 diabetes mellitus (T2DM), but there are limited tools for identifying which patients with T2DM are at the highest risk of developing heart failure.

In this study, we developed and validated the TIMI Risk Score for Heart Failure in Diabetes [TRS-HF(DM)], a novel clinical risk score that identifies patients with T2DM who are at heightened risk for hospitalization due to heart failure.

Fortunately, the risk score also identifies patients who have the greatest absolute reduction in the risk of hospitalization for heart failure with a new class of glucose-lowering therapies called sodium-glucose cotransporter-2 (SGLT2) inhibitors. 

MedicalResearch.com: What should readers take away from your report?

Response: The components of the risk score highlight the fact that underlying heart and kidney problems are key drivers of the risk for heart failure hospitalization in patients with type 2 diabetes mellitus.

Our study also confirms that SGLT2 inhibitors reduce the relative risk of hospitalization for heart failure in all patients with type 2 diabetes mellitus; however, by using TRS-HF(DM), clinicians can better educate patients about their risk for heart failure hospitalization and identify those patients who have the greatest absolute reduction in risk of hospitalization for heart failure with SGLT2 inhibitors.

MedicalResearch.com: What recommendations do you have for future research as a result of this work?

Response: There is still much more to learn about what drives heart failure risk in patients with T2DM. In future studies, for example, it will be important to consider whether blood biomarkers and genetic information can provide additional insights into which patients with type 2 diabetes mellitus are at heightened risk for heart failure.

MedicalResearch.com: Is there anything else you would like to add?

Response: I have no personal disclosures. The databases used to conduct the study were taken from trials funded by AstraZeneca.

Citation:

Heart Failure Risk Stratification and Efficacy of SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus

 

https://esc365.escardio.org/Congress/ESC-CONGRESS-2019/The-right-glucose-lowering-drugs-for-the-right-patient/195652-heart-failure-risk-stratification-and-efficacy-of-dapagliflozin-in-patients-with-type-2-diabetes-mellitus

ESC Congress 2019

 

JOIN OUR EMAIL LIST

We respect your privacy and will never share your details.

Last Modified: Sep 11, 2019 @ 7:21 pm

 

 

 

The information on MedicalResearch.com is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.